BioAdvance Company Profile
BioAdvance was awarded $33.8 million from the Commonwealthâ€™s share of tobacco settlement monies to grow the life sciences industry in Southeastern Pennsylvania. Fulfilling this mission, BioAdvance is:
Investing in emerging life sciences technologies with the most promising commercialization prospects.
Accelerating the transfer of technology from research laboratories to start-ups and established companies.
Building collaborations between academic, entrepreneurial, corporate, financial, and government partners.
Attracting, retaining, and supporting life sciences entrepreneurs.
BioAdvance has allocated $20 million to its Greenhouse Fund, which provides between $5,000 and $500,000 investments in new therapeutics, biomedical devices, diagnostics and platform technologies that have the potential of improving human health. Another $2.5 million is allocated to each of two initiatives that build on the regionâ€™s unmatched base of academic institutions, research facilities, hospitals and its biosciences industry. One initiative is focused on the emerging field of bioinformatics and the second supports increased access to the regionâ€™s clinical trials capabilities.
Corporation of Southeastern Pennsylvania3701 Market Street
United States of America
Phone: (215) 966-6214
Fax: (215) 966-6215
PHILADELPHIA, Oct. 16, 2012 (GLOBE NEWSWIRE) -- BioAdvance, a leading early-stage investor in life sciences companies, today announced the addition of Gregory R. Harriman, M.D., as Venture Partner, a...
BioAdvance, the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania, today announced commitments of $2.4 million to seven new life science companies, two academic te...
Novira Therapeutics Inc. (Radnor, Pa.) raised $23 million in a series A round co-led by new investors 5AM Ventures and Canaan Partners. New investor WuXi PharmaTech Inc. (NYSE:WX) also participated, a...
Ceptaris Therapeutics Inc. (Malvern, Pa.) said it received a complete response letter from FDA for a topical gel formulation of mechlorethamine to treat early stage mycosis fungoides, a type of cutane...
[Novira Therapeutics Inc.] has raised $23mm in the first tranche of its Series A financing co-led by first-time backers 5AM Ventures and Canaan Partners, which each added a board member (5AMâ€™s partn...
Drugs and Medications
BioAdvance was awarded $33.8 million from the Commonwealthâ€™s share of tobacco settlement monies to grow the life sciences industry in Southeastern Pennsylvania. Fulfilling this mission, BioAdvance i...
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based...
Ossianix is a privately held biopharmaceutical company based in Philadelphia, PA that develops novel biopharmaceuticals for a variety of therapeutic areas. The company utilizes th...
Merganser Biotech is a largely virtual, development only company focusedĂ‚Â on the licensing and development of early stage, novel peptidyl therapeutic approaches to the treatment...
The University City Keystone Innovation Zone is a partnership of BioAdvance, Drexel University, Thomas Jefferson University, University City Science Center, University of Pennsylv...
More Information about "BioAdvance" on BioPortfolio
We have published hundreds of BioAdvance news stories on BioPortfolio along with dozens of BioAdvance Clinical Trials and PubMed Articles about BioAdvance for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioAdvance Companies in our database. You can also find out about relevant BioAdvance Drugs and Medications on this site too.